Número 3 - EII al día

65. Reinish JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure toprednisone in humans and animals retards intrauterine growth. Science1978;202:436-8.66. Gur C, Diav-Citrin O, Shechtman S, et al. Pregnancy outcome after exposureto corticosteroids: a prospective controlled study. Reprod Toxicol2004;18:93-101.67. Gluck PA, Gluck JC. A review of pregnancy outcomes after exposure toorally inhaled budesonide. Curr Med Res Opin 2005; 21:93-101.68. Kihlstrom I, Lundberg C. Teratogenicity study of the new glucocorticoidbudesonide in rabbits. Arzneimittelforchung 1987; 37:43-6.69. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine.Teratology 2002; 65:240-61.70. DeWitte DB, Buick MK, Cyran SE, Maisels MJ. Neonatal pancytopenia andsevere combined immunodeficiency associated with antenatal administrationof azathioprine and prednisone. J Pediatr 1984; 105:625-8.71. Davison JM, Dellagrammatikas H, Parkin JM. Maternal azathioprine therapyand depressed haemopoiesis in the babies of renal allograt patients.Br J Obstet Gynecol 1985;92:233-9.72. Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine forchildbearing patients with inflammatory bowel disease: a retrospectivecohor study. Gastroenterology 2003;124:9-17.73. Nørgård B, Pedersen L, Christensen L., Sørensen H. Therapeutic drug usein woman with Crohn’s disease and birth outcomes: a danish nationwidecohort study. Am J Gastroenterol 2007;102:1406-13.74. Langagergaard, V, Pedersen L, Gislum M, et al. Birth outcome in womentreated with azathioprine or mercaptopurine during pregnancy: A Danishnationwide cohort study. Aliment Pharmacol Ther, 2007. 25:73-81.75. Alstead EM, Ritchie JR, Lennard-Jones JE, et al. Safety of azathioprine in pregnancyin inflammatory bowel disease. Gastroenterology 1990;99:443-6.76. Boulton R, Hamilton M, Lewis A, et al. Fulminant ulcerative colitis in pregnancy.Am J Gastroenterol 1994;89:931-3.77. Alstead EM, Nelson-Piercy C, Inflammatory bowel disease in pregnancy.Gut 2003;52:159-61.78. Kainz A, Harabacz I, Cowlrick IS, et al. Review of the course and outcomeof 100 pregnancies in 84 women treated with tacrolimus. Transplantation2000;70:1718-21.79. Piper JM, Mitchell EF, Ray WA. Prenatal use of metronidazole and birthdefects: no association. Obstet Gynaecol 1993;82:348-52.80. Berkovitch M, Pastuszak A, Gazarian M, et al. Safety of the new quinolonesin pregnancy. Obstet Gynaecol 1994;84:535-8.81. Berkovitch M, Diav-Citrin O, Greenberg R, et al. First-trimester exposureto amoxicillin/clavulanic acid: a prospective, controlled study. Br JClin Pharmacol 2004;58:298-302.82. Bertoli D, Borelli G. Fertility study of rifaximin (l/105) in rats. Chemioterapia1986;5:204-7.83. Xifanan (package insert). Morrisville, NC: Salix Pharmaceuticals, 2005.84. Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab useduring pregnancy for induction or maintenance of remission in Crohn’sdisease. Aliment Pharmacol Ther 2005;21:733-8.85. Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapyfor inflammatory bowel disease—seven years on. Aliment PharmacolTher 2006;23:451-63.86. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenancetreatment in patients with chronic pouchitis: A double-blind,placebo-controlled trial. Gastroenterology 2000;119:305-9.87. Teathon K, Pearson M, Levi AJ, Bjarnason I. Elemental diet in the managementof Crohn’s disease during pregnancy. Gut 1991; 32:1079-81.88. Bergstrand O, Hellers G. Breast-feeding during infancy in patients wholater develop Crohn’s disease. Scan J Gastroenterol 1983; 18:903-6.89. Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol ClinNorth Am 2003;32:323-0.170 • Enfermedad Inflamatoria Intestinal al día - Vol. 7 - Nº. 2 - 2008